Neogen (NEOG) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.09
- Estimate
- $0.06
- Surprise
- +58.8%
- Revenue (period 2026-05-31)
- $225.3M
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
Neogen (NEOG) beat the $0.06 estimate with adjusted EPS of $0.09 — a large 58.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NEOG Sell at 4.8/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +58.8% surprise compares with a +46.7% four-quarter average. Next scheduled report: 2026-10-06.
What argues against it
- Concentration risk — Product: Food Safety segment (71.3%)
- Concentration risk — Geographic: sales to customers outside the U.S. (50.2%)
- Target reached (-16.5% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.58
- Price target
- $13.97
- Stop
- $12.63
- Upside to target
- +2.9%
Risk check: RSI 82 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
NEOG at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.96B
- P/E (fwd)
- 35.7
- 52-week range
- $5.10–$14.18
- Off 52-week high
- 4.2%
- RSI (14)
- 82
- Volume vs avg
- 0.14×
- Score today
- 4.8/10